BioLineRx Ltd. (BLRX)

NASDAQ: BLRX · IEX Real-Time Price · USD
0.700
+0.010 (1.46%)
At close: Nov 25, 2022 12:22 PM
0.750
+0.050 (7.14%)
After-hours: Nov 25, 2022 4:52 PM EST
1.46%
Market Cap 43.27M
Revenue (ttm) n/a
Net Income (ttm) -23.52M
Shares Out 740.77M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 77,537
Open 0.71
Previous Close 0.69
Day's Range 0.688 - 0.71
52-Week Range 0.57 - 3.02
Beta 1.54
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2022

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral inf... [Read more]

Industry Biotechnology
IPO Date Jul 25, 2011
CEO Philip Serlin
Employees 38
Stock Exchange NASDAQ
Ticker Symbol BLRX
Full Company Profile

Financial Performance

Financial Statements

News

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

- Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023 - - Introd...

1 week ago - PRNewsWire

BioLineRx to Report Third Quarter 2022 Results on November 15, 2022

TEL AVIV, Israel, Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited fi...

2 weeks ago - PRNewsWire

BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

- PDUFA target action date set for September 9, 2023 - NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance - Com...

2 weeks ago - PRNewsWire

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel , Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notificat...

3 weeks ago - PRNewsWire

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potentia...

Full data from pharmacoeconomic study will be presented demonstrating significant cost benefits from using motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilizati...

3 weeks ago - PRNewsWire

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

Company to accelerate availability to patients and maximize value through independent commercialization to well-defined U.S. transplant center community Veteran product launch leader Holly May named Pre...

1 month ago - PRNewsWire

BLRX INVESTOR ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Inve...

NEW YORK , Sept. 22, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd.

2 months ago - PRNewsWire

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Co...

Los Angeles, California--(Newsfile Corp. - September 20, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of B...

2 months ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact t...

LOS ANGELES--(BUSINESS WIRE)---- $BLRX #BLRX--The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

2 months ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact th...

LOS ANGELES--(BUSINESS WIRE)---- $BLRX #BLRX--The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

2 months ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact...

Los Angeles, California--(Newsfile Corp. - September 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of B...

2 months ago - Newsfile Corp

EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigati...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd. (NASDAQ: BL...

2 months ago - Business Wire

BioLineRx Announces $15 Million Registered Direct Offering

TEL AVIV, Israel , Sept. 19, 2022 /PRNewswire/ -- BioLineRx Ltd.

2 months ago - PRNewsWire

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital

Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved TEL AVIV, Israel , Sept. 15, 2022 /PRNewswire/ -- BioLineRx Ltd.

2 months ago - PRNewsWire

BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study  Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U.S. ( > $500...

2 months ago - PRNewsWire

BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks - - Announced appointment of commerc...

3 months ago - PRNewsWire

BioLineRx to Report Second Quarter 2022 Results on August 16, 2022

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 11, 2022 /PRNewswire/ -- BioLineRx Ltd.

3 months ago - PRNewsWire

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenoca...

NEW YORK , June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.

4 months ago - PRNewsWire

BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic...

- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide in a...

4 months ago - PRNewsWire

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

- Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic ste...

5 months ago - PRNewsWire

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance - - Progressing cr...

6 months ago - PRNewsWire

BioLineRx to Report First Quarter 2022 Results on May 11, 2022

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 5, 2022 /PRNewswire/ -- BioLineRx Ltd.

6 months ago - PRNewsWire

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, March 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for ...

8 months ago - PRNewsWire

BioLineRx to Report 2021 Annual Results on March 16, 2022

TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its aud...

8 months ago - PRNewsWire

BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerix...

TEL AVIV, Israel, March 3, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced additional positive results from ...

8 months ago - PRNewsWire